A detailed history of Black Rock Inc. transactions in Century Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 2,895,613 shares of IPSC stock, worth $3.85 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,895,613
Previous 1,498,181 93.28%
Holding current value
$3.85 Million
Previous $6.26 Million 17.9%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$2.46 - $4.05 $3.44 Million - $5.66 Million
1,397,432 Added 93.28%
2,895,613 $7.38 Million
Q1 2024

May 10, 2024

SELL
$3.19 - $5.32 $66,399 - $110,735
-20,815 Reduced 1.37%
1,498,181 $6.26 Million
Q4 2023

Feb 13, 2024

SELL
$1.28 - $3.32 $97,405 - $252,645
-76,098 Reduced 4.77%
1,518,996 $5.04 Million
Q3 2023

Nov 13, 2023

SELL
$2.0 - $3.23 $40,160 - $64,858
-20,080 Reduced 1.24%
1,595,094 $3.19 Million
Q2 2023

Aug 11, 2023

BUY
$2.91 - $3.53 $592,839 - $719,149
203,725 Added 14.43%
1,615,174 $5.1 Million
Q1 2023

May 12, 2023

SELL
$3.4 - $5.11 $143,806 - $216,132
-42,296 Reduced 2.91%
1,411,449 $4.9 Million
Q4 2022

Feb 13, 2023

BUY
$4.84 - $11.58 $215,776 - $516,259
44,582 Added 3.16%
1,453,745 $7.46 Million
Q3 2022

Nov 14, 2022

BUY
$8.57 - $13.1 $882,521 - $1.35 Million
102,978 Added 7.88%
1,409,163 $13.9 Million
Q2 2022

Aug 12, 2022

BUY
$7.96 - $12.43 $2.21 Million - $3.45 Million
277,928 Added 27.03%
1,306,185 $11 Million
Q1 2022

May 12, 2022

BUY
$11.62 - $15.92 $2.33 Million - $3.2 Million
200,834 Added 24.27%
1,028,257 $12.9 Million
Q4 2021

Feb 10, 2022

BUY
$13.93 - $23.62 $2.49 Million - $4.22 Million
178,767 Added 27.56%
827,423 $13.1 Million
Q3 2021

Nov 09, 2021

BUY
$20.8 - $31.93 $13.5 Million - $20.7 Million
648,656 New
648,656 $16.3 Million

Others Institutions Holding IPSC

About Century Therapeutics, Inc.


  • Ticker IPSC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,881,800
  • Market Cap $78.3M
  • Description
  • Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 fo...
More about IPSC
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.